Mechanical Circulatory Support: Impella
and Extracorporeal Membrane
Oxygenation (ECMO)
Impella Cardiac Assist Device
Overview and Mechanism
The Impella, manufactured by Abiomed, is the world’s smallest heart pump. It utilizes a
rapidly rotating impeller (up to 50,000 RPM) to actively aspirate blood from the ventricle
and eject it into the aorta (for LV support) or pulmonary artery (for RV support).
Hemodynamic Impact:
Ventricular Unloading: Decreases myocardial oxygen demand (MVO₂ ) and
LVEDP.
Systemic Support: Increases cardiac output, mean arterial pressure (MAP), and
coronary perfusion.
Recovery: Promotes myocardial recovery by reducing ischemic injury and wall
stress.
Clinical Indications and Contraindications
Indications:
High-Risk PCI: Prophylactic support for patients with low ejection fraction (EF <
35%) or complex coronary disease.
Cardiogenic Shock (CS): Includes AMI-CS, where protocols such as the
National Cardiogenic Shock Initiative (NCSI) recommend early insertion before
revascularization.
Post-Cardiotomy Shock: For patients unable to wean from bypass.
Contraindications:
Absolute: Severe aortic stenosis (AVA < 0.6 cm²), mechanical aortic valves,
moderate-to-severe aortic regurgitation, and LV thrombus.
Relative: Severe peripheral arterial disease (PAD), aortic aneurysm, and
heparin-induced thrombocytopenia (HIT).
1.4 Complications and Management
Management involves continuous monitoring via the Impella Controller, titrated
performance levels (P-levels), and a heparin-based purge solution (D5W + 25 U/mL
heparin) to prevent motor thrombosis.
Key Complications:
Vascular: Limb ischemia (10–15% in large sheaths), hematoma, and
retroperitoneal hemorrhage.
Device-Related: Hemolysis due to red cell trauma, malposition (suction events),
and aortic valve injury.
Systemic: Stroke, acute kidney injury (AKI), and infection.
Part II: Extracorporeal Membrane Oxygenation
(ECMO)
Modalities
ECMO functions as a temporary artificial heart and/or lung by circulating blood through
an external gas exchanger.
VV-ECMO: Provides respiratory support only. Blood is drained from and returned
to the venous system. It is the standard for refractory ARDS.
VA-ECMO: Provides both cardiac and respiratory support. Blood is drained from
a vein and returned to a systemic artery, bypassing the heart and lungs.
VAV-ECMO: A hybrid used to prevent "Harlequin syndrome" (differential
hypoxia) by returning oxygenated blood to both the arterial and venous systems.
Circuit Components
Centrifugal Pump: Magnetically levitated pumps provide non-pulsatile flow.
Membrane Oxygenator: Uses a polymethylpentene (PMP) membrane for O₂
and CO₂ exchange.
Heat Exchanger: Maintains normothermia.
Cannulae: Large-bore (15–25 Fr) for drainage and return.
Indications and Contraindications
Indications:
Respiratory (VV): Severe ARDS (PaO₂ /FiO₂ < 80), status asthmaticus, or
bridge to lung transplant.
Cardiac (VA): Refractory cardiogenic shock, Extracorporeal CPR (ECPR) for
cardiac arrest, and massive pulmonary embolism.
Contraindications:
Absolute: Irreversible brain injury, terminal malignancy, or unrecoverable multiorgan failure.
Relative: Severe aortic regurgitation (increases LV load in VA-ECMO), severe
PAD, and advanced age with significant comorbidities.
Clinical Management
Anticoagulation: Unfractionated heparin targeting aPTT 60–80 seconds or ACT
180–200 seconds.
VA-ECMO Targets: Flow of 60–80 mL/kg/min, MAP > 60 mmHg, and ScvO₂ >
70%.
VV-ECMO Ventilation: "Ultra-protective" settings (TV 3–4 mL/kg) to allow lung
rest.
LV Venting: Because VA-ECMO increases afterload, venting via IABP or Impella
is often necessary to prevent pulmonary edema.
Complications
Limb Ischemia: Most feared in femoral VA-ECMO; requires a distal perfusion
cannula (DPC).
Bleeding: Occurs in 20–40% of cases (intracranial, GI, or surgical sites).
Harlequin Syndrome: Occurs in VA-ECMO when the failing native heart ejects
deoxygenated blood to the upper body while the ECMO supports the lower body.
Circuit Failure: Oxygenator clotting or pump thrombosis.
References
1. Dangas, G.D., et al. (2014). Am J Cardiol, 113(2), 222-228.
2. Maini, B., et al. (2014). Catheter Cardiovasc Interv, 83(6), E183-E192.
3. Gregory, D., et al. (2013). J Manag Care Med, 16(1), 61-69.
4. Gregory, D., et al. (2013). Am Health Drug Benefits, 6(2), 88-99.
5. O’Neill, W.W., et al. (2012). Circulation, 126(14), 1717-1727.
6. O’Neill, W.W., et al. (2014). J Interviev Cardiol, 27(1), 1-11.
7. Roos, J.B., et al. (2013). J Med Econ, 16(3), 3381-390.
8. Abiomed. (2024, September 10) Global Patients - Fiscal Year. Retrieved from
Salesforce database.
9. https://www.ncbi.nlm.nih.gov/books/NBK576426/